loteprednol etabonate · Alcon Labs Inc · NDA 210933
Eysuvis
Earliest generic entry, as listed
3 May 2033
Blocked by patent: US 10058511, US 10646436, US 10688045, US 10857096, US 10940108, US 10945948, US 10993908, US 11219596, US 11596599, US 11642317, US 11872318, US 12115246, US 9056057, US 9393213, US 9532955, US 9737491, US 9827191.
Listed patents · 17 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10058511 | drug product, use U-2492 · sets the listed date | 3 May 2033 |
| US 10646436 | drug product · sets the listed date | 3 May 2033 |
| US 10688045 | drug product · sets the listed date | 3 May 2033 |
| US 10857096 | use U-2985 · sets the listed date | 3 May 2033 |
| US 10940108 | use U-2985 · sets the listed date | 3 May 2033 |
| US 10945948 | use U-2985 · sets the listed date | 3 May 2033 |
| US 10993908 | use U-3117 · sets the listed date | 3 May 2033 |
| US 11219596 | use U-2985 · sets the listed date | 3 May 2033 |
| US 11596599 | use U-2985 · sets the listed date | 3 May 2033 |
| US 11642317 | drug product · sets the listed date | 3 May 2033 |
| US 11872318 | drug product · sets the listed date | 3 May 2033 |
| US 12115246 | drug product, use U-2985 · sets the listed date | 3 May 2033 |
| US 9056057 | drug product, use U-2491 · sets the listed date | 3 May 2033 |
| US 9393213 | drug product · sets the listed date | 3 May 2033 |
| US 9532955 | use U-2491 · sets the listed date | 3 May 2033 |
| US 9737491 | use U-2492 · sets the listed date | 3 May 2033 |
| US 9827191 | drug product, use U-2985 · sets the listed date | 3 May 2033 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210933 · 001 · RLD | suspension/drops, ophthalmic | 0.25% | 3 May 2033 |